clinical trial · NCT07490613
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase1·recruiting·n = 99
Multiple MyelomaSHR-3836 administered as multiple doses.
brief summary
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
started
Jun 2, 2026
primary completion
Apr 1, 2028
completion
Apr 1, 2029
last updated
Jun 4, 2026
official title
An Open-label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-3836 in Patients With Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol